Erasca Secures $225M in Follow-On Offering, Bolsters RAS-Focused Pipeline Amid Investor Optimism
Biotech firm Erasca, Inc. raised $225 million in a January 2026 follow-on equity offering, providing a substantial runway for its clinical-stage RAS-targeted cancer therapies. The capital infusion, alongside promising updates for programs like ERAS-0015 and ERAS-4001, has reignited debate on the company's valuation and path to commercialization.